TITLE: Genzyme Corporation
FOCUS AREAS: Rare genetic diseases, multiple sclerosis, thyroid cancer, cardiovascular diseases.
CONTACT: Visit PeopleFinder for email and phone number (paid subscribers only)
PROFILE: David Meeker joined Genzyme in 1994 and has been the company’s president and CEO since 2011. According to his professional bio:
David Meeker was appointed President and Chief Executive Officer of Genzyme, a Sanofi company in October 2011. Genzyme is a global biotechnology leader committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs. Dr. Meeker oversees and provides the vision for the company’s two business units – Rare Diseases and Multiple Sclerosis – as well as its long-standing relationships with patient communities and dedicated workforce of nearly 8,000 employees. As an Executive Vice President of Sanofi, he is a member of the Executive Committee.
Dr. Meeker joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program. Subsequently, as Vice President, Medical Affairs, he was responsible for the development of rare disease therapies that today represent transformative and life-saving advancements in medicine for patients. Prior to the merger with Sanofi, Dr. Meeker was Chief Operating Officer, responsible for Genzyme’s commercial organization, overseeing its business units¸ country management organization and global market access functions. He played an important role in the integration with Sanofi.
Prior to joining Genzyme, Dr. Meeker was the Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. He has authored more than 40 articles and multiple book chapters.
Dr. Meeker received his MD from the University of Vermont Medical School. He completed the Advanced Management Program at Harvard Business School in 2000.
You can learn more about Meeker on the Sanofi and Fierce Biotech websites. In December 2015, he was appointed to the board of directors of Rhythm, a biopharmaceutical company that develops peptide therapeutics for rare genetic metabolic disorders.